NCT06246396RecruitingPhase 4
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension
Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 30 Jan 2024
- Start date
- 8 Jan 2025
- Primary completion date
- 31 Jul 2028
- Lead sponsor
- University of Florida
- Diseases
- High blood pressure
- NCT number
- NCT06246396
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 120
- From 8 Jan 2025 to the primary completion date, 31 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent (≤3 months prior), ongoing, or expected use of oral antibiotics
- History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months
- Evidence of alcoholism or drug abuse
Other illness
- Known hypersensitivity or contraindication to minocycline or other tetracyclines
- Known secondary hypertension
- History of hypertensive crisis, defined as any in-patient hospitalizations for hypertensive crisis/emergency within the past year
- History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of \>20 mm Hg or DBP of \>10 mm Hg within 3 minutes of standing) in the past year
- Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)
Lab values
- Estimated glomerular filtration rate (eGFR) of \<45mL/min/1.73m2, using the MDRD equation
Other
- Current pregnancy or anticipated pregnancy during the study.
Who the study is looking for
- Age ≥18 years
- Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP ≥125 mm Hg or diastolic BP ≥80 mm Hg) while being adherent to a stable (no changes in ≥14 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed diuretic or unable to tolerate a diuretic.
- The participant agrees to have all study procedures performed
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UF Clinical Research Center (UF CRC) - CTSI Coordinator of this site? Confirm its status | Gainesville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.